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Immunogenicity and Safety of Diphtheria-tetanus Vaccine 
in Adults 
This study was conducted to evaluate the immunogenicity and safety of diphtheria–
tetanus (Td) vaccine in adults over 40 yr old who had never received a diphtheria-tetanus- 
pertussis (DTP) vaccination. A total of 242 subject completed three-doses of Td vaccination 
and subsequent assays for immunogenicity. Before vaccination, 33.9% and 96.7% 
participants showed antibody levels of diphtheria and tetanus, respectively, which were 
below protective level (<0.1 U/mL). After the first dose of Td vaccine, 92.6% and 77.6% 
of subjects gained protective antibody concentrations (≥0.1 U/mL) for diphtheria and 
tetanus, with an increase to 99.6% and 100% after the third dose. Local and systemic 
adverse events occurred in 37.9% and 15.5% of the subjects. No serious adverse event 
requiring an unscheduled hospital visit occurred. In conclusion, three-doses of Td 
vaccination to unimmunized adults are safe and effective in inducing protective immunity 
against diphtheria and tetanus.
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Infectious Diseases, Microbiology & Parasitology
INTRODUCTION
Diphtheria and tetanus can be only prevented by vaccination 
because immunity against these diseases is rarely acquired, even 
by natural infections (1, 2). To maintain long-term protective 
immunity against diphtheria and tetanus, booster immuniza-
tion is essential for adolescents and adults (3, 4). In most coun-
tries, booster immunization of diphtheria and tetanus is recom-
mended to be performed every 10 yr in people who had com-
pleted DTP vaccination at 4–5 yr old. Booster Td vaccine is rec-
ommended to start at the age of 11–12 yr (5, 6).
  In Korea, the diphtheria-tetanus-whole cell pertussis (DTwP) 
vaccine was introduced in 1958. Therefore, those who were 
born before 1958 had never been vaccinated with either DTwP 
or diphtheria-tetanus-acellular pertussis (DTaP) vaccine intro-
duced in 1982. In Korea, only 1-16 cases of tetanus have been 
reported since 2000; and not a single case of diphtheria has been 
reported since 1987. However, seroepidemologic studies revealed 
that there were groups vulnerable to diphtheria and tetanus (7-
9). More than 90% of the study population had antibody levels 
against tetanus and about 45% had antibody levels against diph-
theria, with concentrations of less than 0.1 U/mL among Kore-
an adults over the age of 40 yr. Also the mean antibody levels of 
diphtheria and tetanus were inversely related with age (8, 9). 
These findings, together with the large epidemic of diphtheria 
in the former Soviet Union in the 1990s and the prevalent diph-
theria in Asian countries, urged us an introduction of Td vac-
cine to our country (10-12).
  After an amendment to the School Health Law in 2005, mid-
dle schools were stipulated to confirm Td vaccination upon their 
admission. The vaccination rate is now approximately 40% in 
11-12 yr old (7). The effectiveness and safety of booster injection 
of Td vaccine in pre-adolescent and adolescent were reported 
in Korea (13, 14). But this vaccine is rarely done in adults, except 
for tetanus prophylaxis in cases of traumatic injuries.
  We conducted this study to assess the immunogenicity and 
safety of three-doses of Td vaccination according to age, sex, 
and vaccine dose, in Korean adults aged 40 yr or older who had 
had an opportunity to receive neither DPT nor Td vaccines, in 
order to formulate concrete evidence of efficacy of Td vaccine 
for adults.Choi J-H, et al.  •  Immunogenicity and Safety of Td Vaccine for Unimmunized Adults
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MATERIALS AND METHODS
Study subjects and design
Adults (40 yr or older), who had not received DPT or Td vacci-
nation and who were willing to participate in this study, were 
enrolled. People who had mild systemic diseases such as dia-
betes mellitus or hypertension which were controlled by oral 
medications and cared for in outpatients clinics were allowed 
to be included. The study was conducted as a multicenter, non-
randomized, open label phase 4 study from August 2007 to De-
cember 2008 in five hospitals in Korea.
  After agreement, history taking and physical examinations 
were done. A complete blood cell count, blood chemistry in-
cluding liver function, kidney function, and glucose levels were 
checked. 
Vaccine and administration
A 0.5 mL dose of Td vaccine (SK Chemical Td-pur
®, Seoul, Ko-
rea), containing 1.5 limes flocculation unit (Lf) diphtheria tox-
oid and 5 Lf tetanus toxoid with 1.5 mg aluminum hydroxide 
was given three times intramuscularly into the deltoid, via pre-
filled syringes with 25-gauge needle of length 2.54 cm. The first 
dose of the vaccine was administered immediately after screen-
ing and enrollment, the second dose was injected 4 weeks after 
the first dose, and the third dose was administered 5 to 6 months 
after the second dose.
Evaluation of immunogenicity
Blood samples (5 mL) were collected before injection, 4 weeks 
after the first injection and 4 weeks after the third injection. Se-
rum samples were kept at -70°C until analysis. Two different 
kinds of enzymes linked immunosorbent assay kits (kit number 
RE56191 for diphtheria and RE56901 for tetanus) from same 
company (IBL, Hamburg, Germany) were used to determine 
the serum levels of antibodies to diphtheria and tetanus, accord-
ing to manufacturer’s instructions. Briefly, 100 μL of each stan-
dard and diluted test serum were put into the wells coated with 
either the diphtheria or tetanus antigens. The plate was covered 
and incubated 60 min at room temperature. After discarding the 
incubated solution, the plate was washed three times with 300 
μL of diluted wash buffer. A total of 100 μL of enzyme conjugate 
was put into each well and incubated for 30 min at room tem-
perature. After discarding the incubation solution, the plate was 
washed three times with 300 μL of diluted wash buffer. After the 
addition of substrate and stop solution, 100 μL of TMB (3,3´,5,5´- 
tetramethylbenzidine base) substrate solution was put into each 
well. After incubating 20 min at room temperature in the dark, 
the substrate reaction was stopped by adding 100 μL of TMB 
stop solution into each well. Optical density was measured with 
a photometer at 450 nm. The levels of antibodies in the samples 
were read by the standard curve obtained from the standard 
samples. Antibody levels ≥0.1 U/mL against diphtheria or teta-
nus were considered indicative of seroprotection.
Evaluation of safety
Subjects were given diary cards and asked to record any local 
adverse events (itching, pain, redness, and swelling at the injec-
tion site) or systemic adverse events (fatigue/malaise, fever, gas-
trointestinal problems, headache, and respiratory symptoms) 
that occurred during the 2-week (days 0-14) follow-up period 
after the vaccination. All subjects were monitored for an addi-
tional 2-weeks (days 15-28), as a safety follow-up period, for 
unscheduled hospital visits and serious adverse events (death, 
life threatening event, hospitalization, any event leading to se-
quelae). Unsolicited adverse events and serious adverse events 
that occurred during the 4-week (days 0-28) study period were 
also recorded. Causal relationships between adverse events and 
the vaccination were evaluated by the investigators. 
Statistical methods 
Geometric mean concentration (GMC) and the seroprotection 
rate were calculated with 95% confidence interval (CI) for each 
antibody measured at each blood sampling time point. The mean 
of changes in antibody concentrations between pre- and post-
vaccination was analyzed with paired t-test. The difference of 
antibody concentrations by age and gender was analyzed with 
ANOVA or t-test at each blood sampling time point.
  All adverse events (solicited and unsolicited) recorded in re-
port forms were classified into the system organ class, accord-
ing to preferred terms. The incidence rate of adverse events and 
its 95% CI were estimated and analyzed using chi-squared-test 
or Fisher’s exact test. 
Ethics statement 
The protocol and associated documents were reviewed and ap-
proved by the ethics committee of each study hospital. The num-
bers of the approvement documents of each hospital are listed 
as follows: Incheon St. Mary’s Hospital (OCMC07MI088), Yeoui-
do St. Mary’s Hospital (SCMC07MI014), Bucheon Soonchun-
hyang University Hospital (07-32), National Health Insurance 
Company Ilsan Hospital (2007-41), and Kangdong Sacred Heart 
Hospital (08-20). Written informed consent was obtained from 
all subjects.
RESULTS
Study population
A total of 290 subjects were enrolled. During the follow-up peri-
od, 37 subjects did not complete the three-times injections of 
Td vaccine and 11 subjects did not give the three blood samples. 
Demographic characteristics of subjects are described in Table 
1. Subjects were classified into three groups according to age. Choi J-H, et al.  •  Immunogenicity and Safety of Td Vaccine for Unimmunized Adults
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Immunogenicity 
Two hundred and forty-two subjects completed the three doses 
of vaccinations and blood samplings for assays. Prior to vaccina-
tion (Pre), GMCs for anti-diphtheria and anti-tetanus antibody 
were 0.3489±0.5255 U/mL and 0.0311±0.0629 U/mL, respec-
tively. Eighty-two of 242 (33.9%) and 234 of 242 (96.7%) partici-
pants showed antibody levels of diphtheria and tetanus of less 
than 0.1 U/mL, respectively. After the first dose of Td vaccina-
tion (Post 1), 224 (92.6%) and 188 (77.6%) participants showed 
antibody levels of more than 0.1 U/mL for diphtheria and teta-
nus, respectively. After the third dose vaccination (Post 3), 241 
(99.6%) and 242 (100%) participants revealed antibody levels  
of more than 0.1 U/mL for diphtheria and tetanus, respectively 
(Fig. 1). GMCs for anti-diphtheria antibody and anti-tetanus 
antibody were 1.8210±1.2820 U/mL and 1.3159±2.1261 U/mL 
each, after the first dose; and 2.0629±0.9351 U/mL and 4.4267± 
3.0746 U/mL each, after the third dose. 
  There was no difference according to age groups with regard 
to gaining anti-diphtheria and anti-tetanus antibodies after 
three-doses of vaccination. There was, however, a significant 
difference in antibody formation found according to the age 
group, after the first dose of vaccination. The older age groups 
(group II and III) showed a higher antibody levels for diphthe-
ria (P=0.006). In contrast, the older age groups showed a lower 
antibody levels for tetanus compared to the younger age (group 
I) (P=0.001) (Tables 2, 3).
  Analysis of seroprevalance among subjects separated by sex 
revealed a significantly higher proportion of pre-vaccination 
antibody levels ≥0.1 IU/mL to diphtheria (P=0.004) and tetanus 
(P<0.001) among men compared to women. Post-vaccination 
seroprevalence did not show significant difference according to 
sex (diphtheria, P=0.845 and 1.000 after first and third dose; tet-
anus, P=0.179 and 1.000 after first and third dose of Td vaccine). 
  Although 66.1% of subjects showed antibody levels to diph-
theria ≥1.0 U/mL after one-dose of Td vaccination, only 28.5% 
of subjects showed antibody levels ≥1.0 U/mL to tetanus. After 
three-doses of Td vaccination, 83.1% and 93.8% of subjects 
achieved antibody levels ≥1.0 U/mL to diphtheria and tetanus, 
respectively (Fig. 1). 
Table 1. Demographic characteristics of vaccinee
Characteristics Categories No. (%)
Gender Male
Female
   84 (29.0)
 216 (71.0)
Age (yr) Mean±STD
Min-Max
Range 
   40-49
   50-59
   ≥60
55.9±10.6
40.0-85.0
 110 (37.9)
   56 (19.3)
 124 (42.8)
Concurrent medical conditions  No
Yes
   Hypertension
   Diabetes mellitus
   Hepatitis B carrier
   Rheumatoid arthritis
   Others
 202 (69.7)
   88 (30.3)
   41 (14.1)
 14 (4.8)
   3 (1.0)
   2 (0.7)
 28 (9.7)
Total 290 (100)
Fig. 1. Distribution of antibody titers pre- and post-vaccination of Td vaccine. 
(A) diphtheria; (B) tetanus; Pre, before first dose of vaccination; Post 1, 4 weeks after first dose of vaccination; Post 3, 4 weeks after third dose of vaccination.
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Table 2. Anti-diphtheria antibody responses following vaccination according to age 
groups
Group
Age  
(yr)
Antibody titer 
(U/mL)
Pre Post 1 Post 3
No. (%) No. (%) No. (%)
I 40-49 <0.01
0.01-0.09
≥0.1
Total
0 
 40 (41.2)
 57 (58.8)
97 (100)
0 
 13 (13.4)
 84 (86.6)
97 (100)
0 
 1 (1.0)
 96 (99.0)
97 (100)
II 50-59 <0.01
0.01-0.09
≥0.1
Total
 1 (2.1)
 17 (35.4)
 30 (62.5)
48 (100)
 1 (2.1)
 1 (2.1)
 46 (95.8)
48 (100)
0 
0 
48 (100)
48 (100)
III ≥60 <0.01
0.01-0.09
≥0.1
Total
0 
 24 (24.7)
 73 (75.3)
97 (100)
0 
 3 (3.1)
 94 (96.9)
97 (100)
0 
0 
97 (100)
97 (100)
P value 0.026  0.006 1.000
Pre, before first dose of vaccination; Post 1, 4 weeks after first dose of vaccination; 
Post 3, 4 weeks after third dose of vaccination.Choi J-H, et al.  •  Immunogenicity and Safety of Td Vaccine for Unimmunized Adults
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Safety 
During the 7-month follow-up period after the vaccination, so-
licited local adverse events occurred in 110 (37.9%) subjects. 
Solicited systemic adverse events occurred in 45 (15.5%) sub-
jects (Table 4). Pain at the injection site was the most common 
local adverse event, and malaise was the most common system-
ic adverse event. Febrile episodes were observed in less than 3% 
of subjects after each vaccination. All of the adverse events re-
solved within 7 days without specific medical care, and no seri-
ous adverse event requiring an unscheduled hospital visit oc-
curred. The rate of adverse events according to vaccination dose 
were 31.0%, 22.9%, and 26.5% after each injection and there was 
no statistical difference according to vaccination frequency (P= 
0.09). The differences in the rate of adverse events according to 
sex and age groups were not evaluated. 
 
DISCUSSION
This study was conducted to evaluate the immunogenicity and 
safety of the Td vaccine in Korean adults aged 40 yr old or older 
who had not received primary vaccination against diphtheria 
and tetanus. The results showed satisfactory immunogenicity 
and acceptable adverse events in this population. 
  In Korea, DTwP vaccine was introduced in 1958 and DTaP 
vaccine has been used for primary and booster immunizations 
since 1982 (7–9). A DTaP immunization coverage of more than 
90% has resulted in a marked decrease in the prevalence of diph-
theria and neonatal tetanus, and no case of diphtheria has been 
reported since 1987 (7, 8). There was a temporary decrease in 
DTaP coverage because of misunderstood contraindications of 
the vaccine and exaggerated reports of unconfirmed adverse 
events. Under these circumstances, around 10 cases of tetanus 
were reported annually in Korea (15) and one case of polyneu-
ropathy assumed to be caused by a diphtheria infection was re-
ported (16). Because immunity against diphtheria and tetanus 
wanes in the absence of routine administration of booster vac-
cinations among adolescents and adults, cohorts of susceptible 
people increase. A previous seroepidemiologic Korean study 
reported that 48-89% of studied subjects had antibody against 
diphtheria of less than 0.1 U/mL according to age groups. Sub-
jects who were 20-49 yr old showed lower GMCs compared to 
subjects older than 50 yr old. The study also showed that about 
90% of subjects over 40 yr of age had antibodies against tetanus 
of less than 0.1 U/mL, with 20% of subjects in this age group less 
than 0.01 U/mL (8, 9).
  Seroepidemiologic evaluation of pre-vaccination state re-
vealed again that 33.9% and 96.7% of participants did not have 
protective immunity against diphtheria and tetanus, respective-
ly. One-dose of Td vaccination provided protective immunity in 
92.6% and 77.6% of subjects against diphtheria and tetanus, re-
spectively. One confusing results was that the participants in the 
older age groups tended to achieve higher antibody levels against 
diphtheria. This result was caused by a greater proportion of the 
older age groups that were already maintaining a higher levels 
of antibodies against diphtheria before vaccination. This phe-
nomenon was also observed in a previous domestic study. Old-
er people maintain a higher antibody levels against diphtheria 
possibly because of long-term exposure to diphtheria before the 
vaccine era, which thereby stimulated natural immunity (8). 
  Three-doses of Td vaccination provided acceptable protective 
immunity against diphtheria and tetanus in all participants. 
These results are compatible to previous studies which revealed 
that more doses of Td vaccination could provide more protective 
immunity and prevent development of severe diseases, espe-
cially for diphtheria (17-19). These studies provided valuable 
Table 3. Anti-tetanus antibody responses following vaccination according to age 
groups
Group
Age  
(yr)
Antibody titer 
(U/mL)
Pre Post 1 Post 3
No. (%) No. (%) No. (%)
I 40-49 <0.01
0.01-0.09
≥0.1
Total
 29 (29.9)
 68 (70.1)
0 
97 (100)
 1 (1.0)
 8 (8.3)
 88 (90.7)
97 (100)
  0 
  0 
97 (100)
97 (100)
II 50-59 <0.01
0.01-0.09
≥0.1
Total
   8 (16.7)
 40 (83.3)
0 
48 (100)
0 
 10 (20.8)
 38 (79.2)
48 (100)
  0 
  0 
48 (100)
48 (100)
III ≥60 <0.01
0.01-0.09
≥0.1
Total
 27 (27.8)
 62 (63.9)
 8 (8.3)
97 (100)
 4 (4.1)
 31 (32.0)
 62 (63.9)
97 (100)
  0 
  0 
97 (100)
97 (100)
P value 0.004  <0.001 
Pre, before first dose of vaccination; Post 1, 4 weeks after first dose of vaccination; 
Post 3, 4 weeks after third dose of vaccination.
Table 4. Incidence of solicited adverse events during 7 months follow-up period after 
vaccination
Number of 
subjects
95% CI
Number  
of AEs
Total 
number  
of subjects
No. (%) (Lower, Upper) No. No.
Total
   Total
   Local AE
   Systemic AE
121 (41.7)
110 (37.9)
  45 (15.5)
(36.1, 47.4)
(32.4, 43.5)
(11.4, 19.7)
585 
417 
124 
290 
290 
290 
First dose
   Total
   Local AE
   Systemic AE
  90 (31.0)
  81 (27.9)
  29 (10.0)
(25.7, 36.4)
(22.8, 33.1)
(6.6, 13.5)
253 
176 
  56 
290 
290 
290 
Second dose
   Total
   Local AE
   Systemic AE
  60 (22.9)
  52 (19.9)
17 (6.5)
(17.8, 28.0)
(15.0, 24.7)
(3.5, 9.5)
157 
112 
  34 
262 
262 
262 
Third dose
   Total
   Local AE
   Systemic AE
  67 (26.5)
  59 (23.3)
22 (8.7)
(21.1, 31.9)
(18.1, 28.5)
(5.2, 12.2)
175 
129 
  34 
253 
253 
253 
AE, adverse event.Choi J-H, et al.  •  Immunogenicity and Safety of Td Vaccine for Unimmunized Adults
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data about the effect of Td vaccine on diphtheria, especially after 
a large outbreak in the former Soviet Union, but the effect on 
tetanus was not evaluated. 
  As there have been no confirmed cases of diphtheria in Korea 
since 1987, a greater emphasis should be placed on tetanus pre-
vention. Although a few cases of tetanus were reported in this 
country, a previous report analyzing 17 adult cases of tetanus 
gave information about the epidemiology of tetanus in Korea 
and led to the acknowledgement of the importance of Td vacci-
nation in adults. In this study, the mean age of tetanus patients 
was 63 yr old (range, 29-87) and 88.2% of the patients received 
neither the primary vaccination nor decennial booster vaccina-
tion. The fatality rate was 23.5% (15).
  Our study strongly suggests that Td vaccination is essential to 
Korean residents over 40 yr of age who never received a primary 
DTaP vaccine and booster Td vaccine. Additionally, to achieve 
sufficient protective immunity to tetanus, at least three-doses 
of Td vaccination is inevitable. Three-doses of Td vaccination 
provided 100% protection against tetanus, even in older people. 
Furthermore, it guaranteed long-term protective immunity 
(GMC ≥1.0 U/mL) in 94% of subjects against tetanus. These re-
sults were supported by a Brazilian study: Weckx et al. assessed 
the immunogenicity of one dose of Td vaccine to elderly sub-
jects (median age 84 yr old). Before vaccination, 18% of the in-
dividuals were susceptible (GMC <0.01 U/mL) to diphtheria 
and 94% were susceptible to tetanus. After one dose of Td vac-
cine, 78% became immune (GMC ≥0.1 U/mL) to diphtheria, 
but 79% remained still susceptible to tetanus. They concluded 
that complete vaccination series appears to be necessary for 
the prevention of tetanus to elderly subjects (20).
  Adverse events following vaccination developed in 41.7% 
(local adverse events 38% and systemic adverse events 16%) of 
subjects. The incidence is markedly less compared to the study 
performed in pre-adolescents and adolescents with the same 
Td vaccine in Korea. More local (68-83%) and systemic (25-32%) 
adverse events were reported in that study. This discrepancy 
might be due to active reporting of adverse events by parents in 
that study (13, 14). A study performed by Khetsuriani et al. (19) 
reported only a 5.3% adverse reaction rate from 248 participants. 
It is generally accepted that the Td vaccine causes fewer and 
milder adverse events than DTaP vaccine (21, 22). 
  Most adverse events reported during this study period were 
mild and resolved spontaneously within 7 days, without special 
treatment such as hospitalization. There were no serious ad-
verse events, such as Arthus reaction or anaphylaxis, requiring 
an unscheduled hospital visit.
  Although two-thirds of the participants were women in this 
study, there was no difference in gaining immunity to diphthe-
ria and tetanus according to sex. This result agrees with the study 
performed by Khetsuiani et al. (19) in the Republic of Georgia, 
with the Td vaccine containing less than 5 Lf of toxoids produced 
by an Indian company. According to this result, we can assume 
that sex is not a limiting factor to gaining immunity to diphthe-
ria and tetanus by Td vaccine, regardless of vaccine manufac-
turing company. 
  In conclusion, we could demonstrate the effectiveness and 
safety of three-doses of Td vaccination in inducing an adequate 
immune response against diphtheria and tetanus, regardless of 
age and sex. 
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